Rise in prescribing for anxiety in UK primary care between 2003 and 2018 : a population-based cohort study using Clinical Practice Research Datalink
© The Authors..
BACKGROUND: Little is known about trends in prescribing of anxiolytics (antidepressants, benzodiazepines, beta-blockers, anticonvulsants, and antipsychotics) for treatment of anxiety. Several changes may have affected prescribing in recent years, including changes in clinical guidance.
AIM: To examine trends in prescribing for anxiety in UK primary care between 2003 and 2018.
DESIGN AND SETTING: A population-based cohort study using Clinical Practice Research Datalink (CPRD) data.
METHOD: Analysis of data from adults (n = 2 569 153) registered at CPRD practices between 2003 and 2018. Prevalence and incidence rates were calculated for prescriptions of any anxiolytic and also for each drug class. Treatment duration was also examined.
RESULTS: Between 2003 and 2018, prevalence of any anxiolytic prescription increased from 24.9/1000 person-years-at-risk (PYAR) to 43.6/1000 PYAR, driven by increases in those starting treatment, rather than more long-term use. Between 2003 and 2006, incidence of any anxiolytic prescription decreased from 12.8/1000 PYAR to 10.0/1000 PYAR; after which incidence rose to 13.1/1000 PYAR in 2018. Similar trends were seen for antidepressant prescriptions. Incident beta-blocker prescribing increased over the 16 years, whereas incident benzodiazepine prescriptions decreased. Long-term prescribing of benzodiazepines declined, yet 44% of prescriptions in 2017 were longer than the recommended 4 weeks. Incident prescriptions in each drug class have risen substantially in young adults in recent years.
CONCLUSION: Recent increases in incident prescribing, especially in young adults, may reflect better detection of anxiety, increasing acceptability of medication, or an earlier unmet need. However, some prescribing is not based on robust evidence of effectiveness, may contradict guidelines, and there is limited evidence on the overall impact associated with taking antidepressants long term. As such, there may be unintended harm.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
The British journal of general practice : the journal of the Royal College of General Practitioners - 72(2022), 720 vom: 21. Juli, Seite e511-e518 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Archer, Charlotte [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
12794-10-4 |
|---|
| Anmerkungen: |
Date Completed 04.07.2022 Date Revised 30.07.2022 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.3399/BJGP.2021.0561 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338448675 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338448675 | ||
| 003 | DE-627 | ||
| 005 | 20231226000711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3399/BJGP.2021.0561 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338448675 | ||
| 035 | |a (NLM)35314430 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Archer, Charlotte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rise in prescribing for anxiety in UK primary care between 2003 and 2018 |b a population-based cohort study using Clinical Practice Research Datalink |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.07.2022 | ||
| 500 | |a Date Revised 30.07.2022 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Authors. | ||
| 520 | |a BACKGROUND: Little is known about trends in prescribing of anxiolytics (antidepressants, benzodiazepines, beta-blockers, anticonvulsants, and antipsychotics) for treatment of anxiety. Several changes may have affected prescribing in recent years, including changes in clinical guidance | ||
| 520 | |a AIM: To examine trends in prescribing for anxiety in UK primary care between 2003 and 2018 | ||
| 520 | |a DESIGN AND SETTING: A population-based cohort study using Clinical Practice Research Datalink (CPRD) data | ||
| 520 | |a METHOD: Analysis of data from adults (n = 2 569 153) registered at CPRD practices between 2003 and 2018. Prevalence and incidence rates were calculated for prescriptions of any anxiolytic and also for each drug class. Treatment duration was also examined | ||
| 520 | |a RESULTS: Between 2003 and 2018, prevalence of any anxiolytic prescription increased from 24.9/1000 person-years-at-risk (PYAR) to 43.6/1000 PYAR, driven by increases in those starting treatment, rather than more long-term use. Between 2003 and 2006, incidence of any anxiolytic prescription decreased from 12.8/1000 PYAR to 10.0/1000 PYAR; after which incidence rose to 13.1/1000 PYAR in 2018. Similar trends were seen for antidepressant prescriptions. Incident beta-blocker prescribing increased over the 16 years, whereas incident benzodiazepine prescriptions decreased. Long-term prescribing of benzodiazepines declined, yet 44% of prescriptions in 2017 were longer than the recommended 4 weeks. Incident prescriptions in each drug class have risen substantially in young adults in recent years | ||
| 520 | |a CONCLUSION: Recent increases in incident prescribing, especially in young adults, may reflect better detection of anxiety, increasing acceptability of medication, or an earlier unmet need. However, some prescribing is not based on robust evidence of effectiveness, may contradict guidelines, and there is limited evidence on the overall impact associated with taking antidepressants long term. As such, there may be unintended harm | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anxiety | |
| 650 | 4 | |a cohort studies | |
| 650 | 4 | |a mental health | |
| 650 | 4 | |a prescribing | |
| 650 | 4 | |a primary health care | |
| 650 | 4 | |a young adult | |
| 650 | 7 | |a Anti-Anxiety Agents |2 NLM | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Benzodiazepines |2 NLM | |
| 650 | 7 | |a 12794-10-4 |2 NLM | |
| 700 | 1 | |a MacNeill, Stephanie J |e verfasserin |4 aut | |
| 700 | 1 | |a Mars, Becky |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Katrina |e verfasserin |4 aut | |
| 700 | 1 | |a Kessler, David |e verfasserin |4 aut | |
| 700 | 1 | |a Wiles, Nicola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The British journal of general practice : the journal of the Royal College of General Practitioners |d 1997 |g 72(2022), 720 vom: 21. Juli, Seite e511-e518 |w (DE-627)NLM012664286 |x 1478-5242 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2022 |g number:720 |g day:21 |g month:07 |g pages:e511-e518 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3399/BJGP.2021.0561 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2022 |e 720 |b 21 |c 07 |h e511-e518 | ||